(Q80206050)
Statements
Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia (English)
Jeffrey H Lipton
Nina Khoroshko
Anatoly Golenkov
Krishnan Nair
Digumarti Raghunadharao
Tim Brummendorf
Kisook Yoo
Bengt Bergstrom
Pegasys CML Study Group
1 March 2007